We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

48 hedge funds and large institutions have $121M invested in Orchestra BioMed in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 7

0.24% more ownership

Funds ownership: 59.42% → 59.66% (+0.24%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less capital invested

Capital invested by funds: $124M → $121M (-$2.95M)

4% less funds holding

Funds holding: 50 → 48 (-2)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Holders
48
Holders Change
-2
Holders Change %
-4%
% of All Funds
0.84%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
10
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$2.2M
2
WAM
Weiss Asset Management
Massachusetts
+$1.14M
3
KPF
K2 Principal Fund
Ontario, Canada
+$987K
4
WRBC
W.R. Berkley Corp
Connecticut
+$976K
5
Marshall Wace
Marshall Wace
United Kingdom
+$790K

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$2.45M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.19M
3
LGM
Logos Global Management
California
-$1.02M
4
MS
Maven Securities
Jersey
-$912K
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$758K
Name Holding Trade Value Shares
Change 		Change in
Stake
DKCM
1
Davidson Kempner Capital Management
New York
$9.6M +$494K +50,000 +5%
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$7.99M -$23.4K -2,373 -0.3%
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$7.91M – – –
BlackRock
4
BlackRock
New York
$7.88M – – –
PI
5
Putnam Investments
Massachusetts
$7.42M – – –
RCM
6
RA Capital Management
Massachusetts
$6.18M – – –
AC
7
Amitell Capital
Singapore
$5.49M +$178K +17,997 +3%
Wellington Management Group
8
Wellington Management Group
Massachusetts
$5M -$1.19M -120,938 -19%
O
9
OrbiMed
New York
$4.95M – – –
PA
10
Perceptive Advisors
New York
$4.45M – – –
KPF
11
K2 Principal Fund
Ontario, Canada
$4.16M +$987K +100,000 +31%
WP
12
Woodline Partners
California
$3.99M – – –
APM
13
Avidity Partners Management
Texas
$3.96M – – –
BC
14
Boxer Capital
California
$3.96M – – –
EC
15
EcoR1 Capital
California
$3.96M – – –
ACP
16
Acuta Capital Partners
California
$3.88M – – –
AAA
17
Affinity Asset Advisors
New York
$2.97M – – –
M
18
Murchinson
Ontario, Canada
$2.97M – – –
Citadel Advisors
19
Citadel Advisors
Florida
$2.57M +$43.3K +4,385 +2%
D.E. Shaw & Co
20
D.E. Shaw & Co
New York
$2.5M +$2.2M +222,717 +747%
GL
21
Governors Lane
New York
$2.47M – – –
SCM
22
Sio Capital Management
New York
$2.47M – – –
IC
23
Ikarian Capital
Texas
$1.95M -$27.9K -2,827 -1%
BFM
24
Boothbay Fund Management
New York
$1.81M +$2.24K +227 +0.1%
ASM
25
ATW SPAC Management
New York
$1.55M – – –
1
2 3

OBIO Hedge Fund Activity: Q3 2021 in Review

48 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q3 2021, worth a combined $121M — down 2.4% from $124M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of OBIO and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 10 added.

The largest buyer was D.E. Shaw & Co, adding an estimated $2.2M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $2.45M sold.

  • 48 institutional investors held Orchestra BioMed (OBIO) as of Q3 2021, down from 50 in Q2 2021.
  • Funds reported $121M of Orchestra BioMed stock for Q3 2021, down 2.4% quarter-over-quarter.
  • 4 funds opened new Orchestra BioMed positions in Q3 2021 and 6 closed out, a net change of -2 holders.
  • The largest Orchestra BioMed buyer in Q3 2021 was D.E. Shaw & Co, an estimated $2.2M added.
  • The largest Orchestra BioMed seller in Q3 2021 was Cormorant Asset Management, an estimated $2.45M sold.

Based on aggregated 13F filings for Q3 2021.